Universal everolimus for malignant neuroendocrine tumours?

Neuroendocrine neoplasms are a heterogeneous group of malignant tumours which vary in localisation, clinical presentation, tumour biology, and prognosis. The tumours derive from the diffuse neuroendocrine cell system, which is spread all over the body. The main tissues affected are thymus, lungs, ga...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 2016-03, Vol.387 (10022), p.924-926
Main Author: Öberg, Kjell
Format: Article
Language:English
Subjects:
Antineoplastic Agents - therapeutic use
Cancer
Chemotherapy
Clinical trials
Cytotoxicity
Endocrine system
Everolimus - therapeutic use
Female
Gastrointestinal Neoplasms - drug therapy
Gastrointestinal tract
Humans
Internal Medicine
Lung Neoplasms - drug therapy
Male
Medical prognosis
Metastasis
Nervous system
Neuroendocrine Tumors - drug therapy
Neuroendocrine Tumors - mortality
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Neuroendocrine neoplasms are a heterogeneous group of malignant tumours which vary in localisation, clinical presentation, tumour biology, and prognosis. The tumours derive from the diffuse neuroendocrine cell system, which is spread all over the body. The main tissues affected are thymus, lungs, gastrointestinal tract, and pancreas. Some tumours present clinical syndromes related to peptide and amine production with clinical syndromes like gastrinoma, insulinoma, VIPoma, and glucagonoma syndromes, and the carcinoid syndrome related to serotonin and tachykinin production from small intestinal neuroendocrine tumours (carcinoids).
ISSN:0140-6736
1474-547X
1474-547X
DOI:10.1016/S0140-6736(15)01234-9